Flag of the European Union EU Clinical Trials Register Help

Clinical trials for dalteparin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: dalteparin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-003085-12 Sponsor Protocol Number: ANT-008 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding i...
    Medical condition: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000394-21 Sponsor Protocol Number: A6301094 Start Date*: 2016-07-20
    Sponsor Name:Pfizer Inc
    Full Title: A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES.
    Medical condition: Acute treatment and secondary prophylaxis of recurrent VTE (venous thromboembolism) in children with or without cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) SI (Completed) PL (Completed) GB (Completed) DE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002962-37 Sponsor Protocol Number: NA_00008675 Start Date*: 2010-09-14
    Sponsor Name:VU Medical Center Amsterdam
    Full Title: Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, ...
    Medical condition: Patients with metastatic or inoperable renal cell cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004708-30 Sponsor Protocol Number: DU176b-D-U311 Start Date*: 2015-05-07
    Sponsor Name:Daiichi Sankyo , Inc.
    Full Title: A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED W...
    Medical condition: venous thromboembolism associated with cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001984-53 Sponsor Protocol Number: ETHIG II Start Date*: 2006-10-11
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss
    Medical condition: Pregnant women with a history of recurrent pregnancy loss, defined as: - 2 or more early (< 12 weeks of gestation) pregnancy losses or - 1 or more late (> 12 weeks of gestation) pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036562 Pregnancy in habitual aborter LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005236-32 Sponsor Protocol Number: FRAG-A001-401 Start Date*: 2009-09-23
    Sponsor Name:Eisai Inc
    Full Title: Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Th...
    Medical condition: Venous thromboembolism in patients with malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003093-40 Sponsor Protocol Number: FADOI_032016 Start Date*: 2017-03-10
    Sponsor Name:FONDAZIONE FADOI
    Full Title: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.
    Medical condition: Venous thromboembolism in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PT (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005409-22 Sponsor Protocol Number: FRAGMIN Start Date*: 2007-09-03
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: RANDOMIZED MULTICENTER STUDY ON DALTEPARIN TREATMENT IN IVF PATIENTS
    Medical condition: couple infertility
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021928 Infertility female LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005850-30 Sponsor Protocol Number: 240/2005 Start Date*: 2006-02-27
    Sponsor Name:Medical University Vienna
    Full Title: Low molecular weight heparin (Fragmin) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial
    Medical condition: Women with a history of pre-eclampsia and babies small for gestational age
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001505-24 Sponsor Protocol Number: 2012-001505-24 Start Date*: 2013-02-25
    Sponsor Name:Academic Medical Center
    Full Title: Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses
    Medical condition: deep vein thrombosis pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066529 Deep vein thrombosis recurrent LLT
    21.1 100000004855 10066738 Recurrent pulmonary embolism LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) IE (Completed) BE (Completed) ES (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001212-29 Sponsor Protocol Number: Prot-0824-2019 Start Date*: 2020-08-26
    Sponsor Name:Aarhus University Hospital, Henrik Birn
    Full Title: Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
    Medical condition: Nephrotic syndrome is defined as severe proteinuria (> 3.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10029167 Nephrotic syndrome with lesion of membranous glomerulonephritis LLT
    20.0 100000004857 10029165 Nephrotic syndrome in diseases classified elsewhere LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000758-29 Sponsor Protocol Number: DU-176B PRT011 Start Date*: 2006-08-18
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: A PHASE IIB, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE-DUMMY, MULTI-CENTER, MULTI NATIONAL, MULTI-DOSE STUDY OF DU-176b COMPARED TO DALTEPARIN IN PATIENTS UNDERGOING ELECTIVE UNILATERAL TOTA...
    Medical condition: Prevention of venous thromboembolism (VTE) after total hip replacement
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2020-001709-21 Sponsor Protocol Number: 2020PI073 Start Date*: 2020-04-29
    Sponsor Name:CHRU de Nancy
    Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis...
    Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002323-15 Sponsor Protocol Number: PREPOSTEROUS Start Date*: 2021-12-10
    Sponsor Name:Helsinki University Hospital
    Full Title: Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicenter, randomized controlled trial
    Medical condition: Venous thromboembolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002438-37 Sponsor Protocol Number: 2005/VCC/0018(WCTU02) Start Date*: 2006-12-07
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer
    Medical condition: Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005784-10 Sponsor Protocol Number: A6301083 Start Date*: 2007-12-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC...
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Completed) GB (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) FR (Completed) ES (Completed) GR (Completed) CZ (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005589-37 Sponsor Protocol Number: RMRHS0095 Start Date*: 2013-03-08
    Sponsor Name:University of Warwick
    Full Title: select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
    Medical condition: Venous Thromboembolism and Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10007050 Cancer LLT
    14.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001566-90 Sponsor Protocol Number: A6301086 Start Date*: 2008-06-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent
    Full Title: A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) ES (Completed) NL (Prematurely Ended) CZ (Completed) FR (Completed) AT (Completed) DK (Prematurely Ended) FI (Prematurely Ended) BE (Completed) LT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021813-22 Sponsor Protocol Number: 781875 Start Date*: 2010-12-23
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: The Anticoagulation of Calf Thrombosis (ACT) Study: A randomised controlled trial comparing standardised anticoagulation versus conservative therapy in the treatment of below knee deep vein thrombo...
    Medical condition: DVT of the calf / below knee region.
    Disease: Version SOC Term Classification Code Term Level
    12 10013878 DVT of calf LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001707-31 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2015-07-10
    Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust
    Full Title: The SCaIPEL study: Survival and Quality of Life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH
    Medical condition: Incidental Pulmonary Embolism in Cancer Patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:32:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA